Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2024

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒

Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	18 January 2024 - “Holding(s) in Company”

99.1

18 January 2024

HALEON PLC

("Haleon" or "the Company") 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

HALEON PLC

UK or Non-UK Issuer

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

GSK plc

City of registered office (if applicable)

BRENTFORD

Country of registered office (if applicable)

United Kingdom

Name	City of registered office	Country of registered office
GSK (No.1) Scottish Limited Partnership	Edinburgh	Scotland
GSK LP Limited	London	England
GSK GP 1 Limited	Edinburgh	Scotland

4. Details of the shareholder

Name	City of registered office	Country of registered office
Vidacos Nominees Limited	London	England

5. Date on which the threshold was crossed or reached

17-Jan-2024

6. Date on which Issuer notified

18-Jan-2024

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	4.170000	0.000000	4.170000	385320110
Position of previous notification (if applicable)	7.420000	0.000000	7.420000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BMX86B70	0	385320110	0.000000	4.170000
Sub Total 8.A	385320110		4.170000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
GSK plc (Chain 1)		2.850000		2.850000%
GSK plc (Chain 1)	GlaxoSmithKline Holdings Limited (Chain 1)	2.850000		2.850000%
GSK plc (Chain 1)	GlaxoSmithKline Finance plc (Chain 1)	2.850000		2.850000%
GSK plc (Chain 1)	Glaxo Group Limited (Chain 1)	2.850000		2.850000%
GSK plc (Chain 2)		1.330000		1.330000%
GSK plc (Chain 2)	GSK LP Limited (Chain 2)	1.330000		1.330000%
GSK plc (Chain 2)	GSK GP 1 Limited (Chain 2)	1.330000		1.330000%
GSK plc (Chain 2)	GSK (No. 1) Scottish Limited Partnership (Chain 2)	1.330000		1.330000%

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

GSK plc is making this notification on behalf of itself and on behalf of GSK LP Limited, GSK GP 1 Limited and GSK (No.1) Scottish Limited Partnership.

This notification relates to the sale by GSK (No.1) Scottish Limited Partnership (an entity indirectly wholly-owned by GSK plc) of a portion of its interest in Haleon plc.

GSK GP 1 Limited is the sole general partner of GSK (No.1) Scottish Limited Partnership.

GSK LP Limited is the sole limited partner of GSK (No.1) Scottish Limited Partnership.Glaxo Group Limited and GSK (No.1) Scottish Limited Partnership hold their shares in Haleon plc via a custodian, Vidacos Nominees Limited, which holds the legal title to those shares on their behalf pursuant to a custody arrangement.

12. Date of Completion

18-Jan-2024

13. Place Of Completion

London, England

Amanda Mellor, Company Secretary

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.